My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
ITC hits record high
May 26,2017

The result was announced during market hours today, 26 May 2017.

Meanwhile, the S&P BSE Sensex was up 286.83 points or 0.93% at 31,036.86.

On the BSE, 22.07 lakh shares were traded on the counter so far as against the average daily volumes of 11.54 lakh shares in the past one quarter. The stock had hit a high of Rs 313.40 so far during the day, which is a record high. The stock hit a low of Rs 300 so far during the day. The stock had hit a 52-week low of Rs 222.05 on 26 December 2016.

The stock had outperformed the market over the past one month till 25 May 2017, advancing 6.58% compared with the Sensexs 2.69% rise. The scrip had also outperformed the market over the past one quarter, gaining 12.8% as against the Sensexs 6.43% rise.

The large-cap company has equity capital of Rs 1214.74. Face value per share is Rs 1.

ITCs board recommended a dividend of Rs 4.75 per share for the year ended March 2017.

ITC is a diversified company, with presence in cigarettes, hotels, paperboards & specialty papers, packaging, agri-business, packaged foods & confectionery, information technology, branded apparel, personal care, stationery and other FMCG products. ITC is a market leader in cigarettes.

Powered by Capital Market - Live News

Ujaas Energy shines after bagging order
May 26,2017

The announcement was made during market hours today, 26 May 2017.

Meanwhile, the S&P Sensex was up 264.51 points or 0.86% at 31,014.54. The S&P BSE Small-cap index was up 224.41 points, or 1.51% at 15,073.14.

On the BSE, 1.75 lakh shares were traded on the counter so far as against the average daily volumes of 2.5 lakh shares in the past one quarter. The stock had hit a high of Rs 36 and a low of Rs 33.70 so far during the day.

The stock had hit a record high of Rs 52.25 on 16 December 2016 and a 52-week low of Rs 19.40 on 29 September 2016. The stock had underperformed the market over the past one month till 25 May 2017, dropping 9.04% compared with 2.69% rise in the Sensex. The scrip had also underperformed the market in past one quarter, declining 4.4% as against Sensexs 6.43% rise.

The small-cap company has equity capital of Rs 20 crore. Face value per share is Re 1.

Ujaas Energy received letter of intent from Arunachal Pradesh Energy Development Agency for design, supply, installation, testing and commissioning of 200 kilowatt peak (kWp) grid connected solar photovoltaic plant at the state assembly building in Itanagar, Arunachal Pradesh.

Ujaas Energys net profit surged 266.5% to Rs 8.54 crore on 113.8% growth in net sales to Rs 97.66 crore in Q3 December 2016 over Q3 December 2015.

Ujaas Energy is engaged in the design of various products and solutions for producing clean energy.

Powered by Capital Market - Live News

Sun Pharma extends recent slide
May 26,2017

Meanwhile, the S&P BSE Sensex was up 272.76 points or 0.89% at 31,022.79.

On the BSE, 9.96 lakh shares were traded on the counter so far as against the average daily volumes of 3.75 lakh shares in the past one quarter. The stock had hit a high of Rs 598.45 and a low of Rs 568.20 so far during the day.

The stock had hit a 52-week high of Rs 854.50 on 5 August 2016 and a 52-week low of Rs 572.40 on 9 November 2016. It had underperformed the market over the past one month till 25 May 2017, sliding 7.89% compared with the Sensexs 2.69% rise. The scrip had also underperformed the market over the past one quarter, declining 12.38% as against the Sensexs 6.43% rise.

The large-cap company has equity capital of Rs 239.93 crore. Face value per share is Rs 1.

Shares of Sun Pharmaceutical Industries (Sun Pharma) have declined 12.48% in six trading sessions to its ruling market price, from its closing of Rs 653.90 on 18 May 2017, ahead of the companys Q4 March 2017 earnings scheduled today, 26 May 2017.

Also, weak quarterly earnings from the companys US subsidiary Taro Pharmaceutical Industries (Taro) announced on 22 May 2017, dampened investors sentiment in Sun Pharma.

Taros net profit fell 27.82% to $83 million on 25.9% decrease in net sales to $196.40 million in Q4 March 2017 over Q4 March 2016. The drop in net sales is due to continuing increased competition and the challenging pricing environment.

On a consolidated basis, Sun Pharmaceuticals Industries net profit declined 11.2% to Rs 1721.85 crore on 8.4% rise in net sales to Rs 7683.24 crore in Q3 December 2016 over Q3 December 2015.

Sun Pharma is a specialty generic pharmaceutical company and Indias top pharmaceutical company.

Powered by Capital Market - Live News

3M India jumps after reporting good Q4 earnings
May 26,2017

The result was announced during market hours today, 26 May 2017.

Meanwhile, the S&P BSE Sensex was up 256.70 points, or 0.83% at 31,006.73.

High volumes were witnessed on the counter. On the BSE, 2,357 shares were traded on the counter so far as against the average daily volumes of 408 shares in the past one quarter. The stock had hit a high of Rs 14,297.35 and a low of Rs 13,274.30 so far during the day.

The stock had hit a record high of Rs 15,200 on 26 July 2016 and a 52-week low of Rs 10,055 on 27 December 2016. The stock had outperformed the market over the past one month till 25 May 2017, advancing 13.5% compared with the Sensexs 2.69% rise. The scrip had also outperformed the market over the past one quarter advancing 17.68% as against the Sensexs 6.43% rise.

The large-cap company has equity capital of Rs 11.27 crore. Face value per share is Rs 10.

3M India provides industrial, automotive, electrical, telecom and safety products.

Powered by Capital Market - Live News

HeidelbergCement India hardens after good Q4 results
May 26,2017

The result was announced after market hours yesterday, 25 May 2017.

The stock had risen 3.49% to Rs 124.70 yesterday, 25 May 2017 ahead of the results.

Meanwhile, the S&P BSE Sensex was up 245.97 points or 0.8% at 30,996. The S&P Small-Cap index was up 209.96 points or 1.41% at 15,058.69.

On the BSE, 62,676 shares were traded in the counter so far as against average daily volume of 69,326 shares in the past one quarter.

The stock had hit a high of Rs 130.65 and a low of Rs 126.50 so far during the day. The stock had hit a 52-week high of Rs 150.55 on 28 October 2016. The stock had hit a 52-week low of Rs 94.25 on 25 May 2016. The stock had underperformed the market over the past one month till 25 May 2017, dropping 7.53% compared with 2.69% rise in the Sensex. The scrip, had, however, outperformed the market in past one quarter, gaining 7.36% as against Sensexs 6.43% rise.

The small-cap cement manufacturing company has equity capital of Rs 226.62 crore. Face value per share is Rs 10.

HeidelbergCement India said that the board of directors recommended a dividend of Rs 2 per share for the financial year ended 31 March 2017 (FY 2017).

HeidelbergCement India is a subsidiary of HeidelbergCement Group, Germany. The company has its operations in Central India at Damoh (Madhya Pradesh), Jhansi (Uttar Pradesh) and in Southern India at Ammasandra (Karnataka).

Powered by Capital Market - Live News

HeidelbergCement India hardens after strong Q4 results
May 26,2017

The result was announced after market hours yesterday, 25 May 2017.

The stock had risen 3.49% to Rs 124.70 yesterday, 25 May 2017 ahead of the results.

Meanwhile, the S&P BSE Sensex was up 245.97 points or 0.8% at 30,996. The S&P Small-Cap index was up 209.96 points or 1.41% at 15,058.69.

On the BSE, 62,676 shares were traded in the counter so far as against average daily volume of 69,326 shares in the past one quarter.

The stock had hit a high of Rs 130.65 and a low of Rs 126.50 so far during the day. The stock had hit a 52-week high of Rs 150.55 on 28 October 2016. The stock had hit a 52-week low of Rs 94.25 on 25 May 2016. The stock had underperformed the market over the past one month till 25 May 2017, dropping 7.53% compared with 2.69% rise in the Sensex. The scrip, had, however, outperformed the market in past one quarter, gaining 7.36% as against Sensexs 6.43% rise.

The small-cap cement manufacturing company has equity capital of Rs 226.62 crore. Face value per share is Rs 10.

HeidelbergCement India said that the board of directors recommended a dividend of Rs 2 per share for the financial year ended 31 March 2017 (FY 2017).

HeidelbergCement India is a subsidiary of HeidelbergCement Group, Germany. The company has its operations in Central India at Damoh (Madhya Pradesh), Jhansi (Uttar Pradesh) and in Southern India at Ammasandra (Karnataka).

Powered by Capital Market - Live News

Volumes jump at Swelect Energy Systems counter
May 26,2017

Swelect Energy Systems clocked volume of 1.28 lakh shares by 13:55 IST on BSE, a 115.02-times surge over two-week average daily volume of 1,000 shares. The stock zoomed by 20% upper circuit level at Rs 421.35 after the company reported net profit of Rs 13 crore in Q4 March 2017, compared with net loss of Rs 1.04 crore in Q4 March 2016. Total income rose 95.67% to Rs 91.75 crore in Q4 March 2017 over Q4 March 2016.

Healthcare Global Enterprises notched up volume of 2.52 lakh shares, a 96.13-fold surge over two-week average daily volume of 3,000 shares. The stock lost 0.67% at Rs 251.05.

Marico saw volume of 31.67 lakh shares, a 33.11-fold surge over two-week average daily volume of 96,000 shares. The stock was down 0.1% at Rs 314.85.

Banco Products (India) clocked volume of 18.73 lakh shares, a 24.25-fold surge over two-week average daily volume of 77,000 shares. The stock advanced 3.76% at Rs 225.

Sequent Scientific saw volume of 10.41 lakh shares, a 19.3-fold rise over two-week average daily volume of 54,000 shares. The stock was up 3.11% at Rs 116.

Powered by Capital Market - Live News

Lupin extends recent losses
May 26,2017

Meanwhile, the S&P BSE Sensex was up 216.99 points or 0.71% at 30,967.02.

On the BSE, 1.14 lakh shares were traded on the counter so far as against the average daily volumes of 1.48 lakh shares in the past two weeks. The stock hit a high of Rs 1,163.60 and a low of Rs 1,115 so far during the day.

The stock had hit a 52-week high of Rs 1,750 on 29 July 2016 and 52-week low of Rs 1,108 on 25 May 2017.

The large-cap company has equity capital of Rs 90.33 crore. Face value per share is Rs 2.

Shares of Lupin have fallen 8.76% in two trading sessions from its closing of Rs 1,227.65 on 24 May 2017, on reports that a foreign brokerage has downgraded the stock to outperform from buy earlier and has also lowered its target price to Rs 1,350 from Rs 1,760 earlier.

According to reports, the global brokerage stated that Lupin expects a challenging FY 2018 due to competitive/regulatory pressures in the US and Japan. US concerns are on account of continued customer consolidation, incremental competition in top products, and slower-than-expected Gavis ramp-up, it said. The brokerage further added that a few critical FY 2019 launches of the company have been pushed out to FY 2020.

Shares of Lupin had fallen 1.71% to settle at Rs 1,227.65 on 24 May 2017 after the company announced weak Q4 earnings during market hours on that day.

Lupins consolidated net profit fell 49.16% to Rs 380.21 crore on 1.33% growth in total revenue from operations to Rs 4253.30 crore in Q4 March 2017 over Q4 March 2016.

During Q4 March 2017, the company made a provision for liability towards its Australian subsidiary amounting to Rs 155.90 crore in respect of compensation for patent litigation towards its Isabelle generic launch in Australia.

Lupins shares witnessed selling pressure in the run-up to the announcement of its Q4 results. They had fallen 5.01% in two trading sessions to settle at Rs 1,249 on 23 May 2017, from its closing of Rs 1,314.90 on 19 May 2017.

Lupin is a pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Powered by Capital Market - Live News

Dr Reddys gets healthier after USFDA clears plant after audit
May 26,2017

The announcement was made after market hours yesterday, 25 May 2017.

Meanwhile, the S&P BSE Sensex was up 179.53 points, or 0.63% to 30,945.12.

The stock had dropped 11.15% in six sessions to Rs 2,427.30 yesterday, 25 May 2017 from a close of Rs 2,731.95 on 17 May 2017.

On the BSE, 24,482 shares were traded in the counter so far, compared with average daily volumes of 40,962 shares in the past one quarter.

At the days high of Rs 2,548.75 hit in early trade, the stock had jumped 5%. The stock had hit a low of Rs 2,431.15 so far during the day. The stock had hit a 52-week high of Rs 3,689 on 20 July 2016 and a 52-week low of Rs 2,400 yesterday, 25 May 2017.

The stock had underperformed the market over the past one month till 25 May 2017, dropping 8.25% compared with 2.69% rise in the Sensex. The scrip also underperformed the market in past one quarter, declining 16.01% as against Sensexs 6.43% rise.

The large-cap drug major has equity capital of Rs 82.87 crore. Face value per share is Rs 5.

Dr Reddys Laboratories said that the United States Food & Drug Administration (USFDA) completed the audit of its formulations Srikakulum plant (SEZ) unit II, in Andhra Pradesh on 25 May 2017 with zero observations.

Dr Reddys Laboratories consolidated net profit rose 175.4% to Rs 337.60 crore on 5.4% decline in net sales to Rs 3554.20 crore in Q4 March 2017 over Q4 March 2016.

Dr Reddys Laboratories is an integrated global pharmaceutical company.

Powered by Capital Market - Live News

Sintex Industries extends Thursdays rally
May 26,2017

Meanwhile, the S&P BSE Sensex was up 206.51 points or 0.67% at 30,956.54. The S&P BSE Small-Cap index was up 189.46 points or 1.28% at 15,038.19.

On the BSE, 1.25 crore shares were traded on the counter so far as against the average daily volumes of 18.69 lakh shares in the past one quarter. The stock had hit a high of Rs 30.90 and a low of Rs 24.85 so far during the day.

The stock had hit a 52-week high of Rs 37.85 on 17 May 2017 and a 52-week low of Rs 17.75 on 25 May 2017. It had outperformed the market over the past one month till 25 May 2017, surging 30.3% compared with the Sensexs 2.69% rise. The scrip had also outperformed the market over the past one quarter, advancing 60.75% as against the Sensexs 6.43% rise.

The small-cap company has equity capital of Rs 55.49 crore. Face value per share is Rs 1.

Shares of Sintex Industries are trading post-scheme of arrangement today, 26 May 2017 after the stock turned ex-scheme of arrangement yesterday, 25 May 2017, for the demerger of its plastics division.

The stock has rallied 68.8% in two trading sessions from its closing of Rs 17.95 on 24 May 2017. It had surged 43.73% in a single trading session yesterday, 25 May 2017 to settle at Rs 25.80 on turning ex-demerger scheme that day.

Sintex Industries board, in September 2016, had approved a composite scheme of arrangement for the demerger of the custom moulding business and the prefab business from Sintex Industries to Sintex-BAPL and Sintex Infra Projects, respectively, each a wholly owned subsidiary of Sintex Plastics Technology (SPTL).

SPTL is expected to start trading on the stock exchanges in next 10-15 days, reports suggested.

Meanwhile, Credit Suisse (Singapore) sold 32.91 lakh shares of Sintex Industries at Rs 104.13 per share in a bulk deal on the NSE on 24 May 2017. On the same day, Merrill Lynch Markets Singapore Pte offloaded 30.17 lakh shares of the company at Rs 105.11.

Sintex Industries consolidated net profit fell 78.7% to Rs 49.54 crore on 132.7% growth in net sales to Rs 661.40 crore in Q4 March 2017 over Q4 March 2016.

Sintex Industries is engaged in spinning, weaving and finishing of textiles.

Powered by Capital Market - Live News

Concor jumps after reporting decent Q4 numbers
May 26,2017

The result was announced after market hours yesterday, 25 May 2017.

Meanwhile, the S&P BSE Sensex was up 211.29 points, or 0.69% at 30,961.32.

On the BSE, 31,000 shares were traded on the counter so far as against the average daily volumes of 64,763 shares in the past one quarter. The stock had hit a high of Rs 1,216.25 and a low of Rs 1,179 so far during the day.

The stock had hit a 52-week high of Rs 1,250.45 on 23 May 2017 and a 52-week low of Rs 844 on 21 December 2016. The stock had underperformed the market over the past one month till 25 May 2017, declining 4.66% compared with the Sensexs 2.69% rise. The scrip had, however, outperformed the market over the past one quarter advancing 21.76% as against the Sensexs 6.43% rise.

The large-cap company has equity capital of Rs 243.72 crore. Face value per share is Rs 10.

Container Corporation of India (Concor)s board recommended a final dividend of Rs7.50 per equity share for the year ended March 2017.

Concor provides logistics solutions. It has the largest network of inland container depots (ICDs)/container freight stations in India. In addition to providing inland transport by rail for containers, it has also expanded to cover management of ports, air cargo complexes and establishing cold-chain. The Government of India (GoI) holds 54.8% stake in Concor (as per the shareholding pattern as on 31 March 2017).

Powered by Capital Market - Live News

Repco Home Finance moves north after strong Q4 numbers
May 26,2017

The result was announced after market hours yesterday, 25 May 2017.

Meanwhile, the S&P BSE Sensex was up 150.51 points or 0.49% at 30,900.54. The S&P BSE Mid-Cap index was up 157.38 points or 1.11% at 14,384.39.

On the BSE, 11,000 shares were traded on the counter so far as against the average daily volumes of 16,598 shares in the past one quarter. The stock had hit a high of Rs 796.30 and a low of Rs 740.35 so far during the day.

The stock had hit a record high of Rs 891.30 on 6 September 2016 and a 52-week low of Rs 499.50 on 20 December 2016. It had underperformed the market over the past one month till 25 May 2017, sliding 2.57% compared with the Sensexs 2.69% rise. The scrip had, however, outperformed the market over the past one quarter, advancing 12.46% as against the Sensexs 6.43% rise.

The mid-cap company has equity capital of Rs 62.56 crore. Face value per share is Rs 10.

Repco Home Finances net interest income rose 20% to Rs 102.90 crore in Q4 March 2017 over Q4 March 2016.

Net interest margin expanded to 4.7% in Q4 March 2017, from 4.6% in Q4 March 2016. Spread expanded to 3.4% in Q4 March 2017, from 3% in Q4 March 2016.

The companys board recommended a dividend of Rs 2 per share for the year ended March 2017.

Repco Home Finance (RHFL) is one of the leading housing finance companies in India. As on 31 March 2017, the company had a total network of 125 branches and 32 satellite centers.

Powered by Capital Market - Live News

Aviation stocks soar after sharp fall in crude oil prices
May 26,2017

Meanwhile, the S&P BSE Sensex was up 135.25 points or 0.44% at 30,885.28.

Jet Airways (India) (up 3.87% to Rs 486.30), SpiceJet (up 4.58% to Rs 108.50) and InterGlobe Aviation (up 2.26% to Rs 1,097.95) gained.

Lower crude oil prices favourably affect aviation firms as jet fuel price, which typically constitute about 50% of airlines operating costs is likely to get reduced as it is directly linked to international crude oil prices. Jet fuel prices are revised by the PSU OMCs at the end of every month based on international crude oil prices.

In the global commodities markets, crude oil prices saw a sharp drop as the Organization of the Petroleum Exporting Countries (OPEC) extended the production cut, but was silent on a long term plan. Brent for July 2017 settlement was down 26 cents at $51.20 a barrel. The contract fell $2.50 a barrel or 4.63% to settle at $51.46 a barrel in the previous trading session.

Opec decided yesterday, 25 May 2017, in Austria to extend cuts in oil output by nine months to March 2018, as the producer group battles a global glut of crude after seeing prices halve and revenues drop sharply in the past three years.

Powered by Capital Market - Live News

Lypsa Gems gains on boards nod for bonus issue
May 26,2017

The result was announced after market hours yesterday, 25 May 2017.

Meanwhile, the S&P BSE Sensex was up 135.97 points or 0.44% at 30,886. The S&P BSE Small-Cap index was up 212.28 points or 1.43% at 15,061.01.

On the BSE, 45,000 shares were traded on the counter so far as against the average daily volumes of 72,505 shares in the past one quarter. The stock had hit a high of Rs 67.50 and a low of Rs 64 so far during the day.

The stock had hit a 52-week high of Rs 96.65 on 6 June 2016 and a record low of Rs 49 on 30 November 2016. It had underperformed the market over the past one month till 25 May 2017, sliding 10.83% compared with the Sensexs 2.69% rise. The scrip had also underperformed the market over the past one quarter, declining 6.6% as against the Sensexs 6.43% rise.

The small-cap company has equity capital of Rs 21.06. Face value per share is Rs 10.

Lypsa Gems & Jewellerys net profit jumped 593.1% to Rs 7 crore on 55.7% growth in net sales to Rs 80.05 crore in Q4 March 2017 over Q4 March 2016.

Lypsa Gems & Jewellery is a wholly owned integrated diamond company sourcing rough diamonds from the major diamond mines and dealers, cutting and polishing them in its own factories & marketing its product to clients across the globe. It also sells diamond-studded jewellery under the Oropel and Lypsa Atelier brand names.

Powered by Capital Market - Live News

Glenmark Pharma advances on USFDA approval for generic drug
May 26,2017

The announcement was made before market hours today, 26 May 2017.

The stock had dropped 8.47% in three sessions to settle at Rs 611.95 yesterday, 25 May 2017 from a close of Rs 668.65 on 22 May 2017.

Meanwhile, the BSE Sensex was up 134.21 points, or 0.44%, to 30,884.24.

On the BSE, 70,809 shares were traded in the counter so far, compared with average daily volumes of 1.1 lakh shares in the past one quarter. The stock had hit a high of Rs 628.70 and a low of Rs 611.95 so far during the day. The stock had hit a 52-week high of Rs 993 on 1 November 2016. The stock had hit a 52-week low of Rs 608.50 yesterday, 25 May 2017.

The stock had underperformed the market over the past one month till 25 May 2017, dropping 32.01% compared with 2.69% rise in the Sensex. The scrip had also underperformed the market in past one quarter, declining 34.48% as against Sensexs 6.43% rise.

The large-cap company has equity capital of Rs 28.22 crore. Face value per share is Re 1.

Glenmark Pharmaceuticals said that Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg, the generic version of Benicar Tablets, 5 mg, 20 mg and 40 mg, of Daiichi Sankyo, Inc.

Glenmarks Olmesartan Medoxomil Tablets will be manufactured by Glenmark Pharmaceuticals in its manufacturing facility located in Goa, India.

According to IMS Health sales data for the 12 month period ended March 2017, the Benicar Tablets, 5 mg, 20 mg and 40 mg market achieved annual sales of approximately $950 million in US.

Meanwhile, the company issued clarification after market hours yesterday, 25 May 2017, that global rating agency S&P has reaffirmed its credit rating as BB as part of their annual review cycle. In addition, they have affirmed BB issue rating on the senior unsecured notes issued last year. However, they have changed the outlook from stable to negative, based on their internally defined criteria.

On a consolidated basis, Glenmark Pharmaceuticals net profit rose 23.5% to Rs 183.76 crore on 10.2% rise in net sales to Rs 2424.41 crore in Q4 March 2017 over Q4 March 2016.

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical organization headquartered at Mumbai, India. The company is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).

Powered by Capital Market - Live News